CVRx names medtech veteran its new CFO
CVRx, the Minneapolis-based medtech company known for its Barostim technology, has named industry veteran John Landry is next chief financial officer (CFO). He officially takes over the role on Oct. 1.
Jared Oasheim, the company’s previous CFO, will remain with CVRx for a short transitional period before stepping down.
“Barostim is changing how physicians treat heart failure and the positive impact it is having on patients’ lives is what drew me to this role,” Landry said in a statement. “I've spent most of my career in the medical device industry helping to build the infrastructure and operating discipline needed as companies scale their commercial efforts. I’m excited to join the CVRx team and see a real opportunity to bring that same operating discipline to support the business as we execute our commercial growth strategy.”
Landry has spent more than 20 years as a financial leader in the medtech space. He currently serves as the CFO of Nyxoah SA, a Belgium-based company focused on developing new obstructive sleep apnea treatments. He has also held leadership positions with Vapotherm, Salient Surgical Technologies, Bottomline Technologies, Hussey Seating Company and Coopers & Lybrand.
“John is exactly the kind of finance leader we need for this next chapter,” Kevin Hykes, president and CEO of CVRx, said in the same statement. “Over the past two decades, he has played a key role in building and financing high growth medical device companies introducing novel therapies like Barostim. He is a hands-on operational leader who has significant commercial and capital markets experience, and who is well known within the investment community. John’s experience driving growth while managing expenses is particularly relevant as we scale Barostim and reach more heart failure patients.”
A closer look at Barostim
Barostim therapy works by sending small electrical pulses to sensors in the neck. The neck’s sensors then send signals to the brain that help regulate the patient’s heart, kidneys and vascular system. While those signals are typically sent without therapy, that function is diminished in heart failure patients; that’s where Barostim comes in.
The Barostim device has gained significant momentum in recent years. It already received both U.S. Food and Drug Administration and CE mark approval, for example, in addition to new Category 1 CPT codes from the American Medical Association.
Michael has more than 19 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.